SYMBIOTEC PHARMALAB (SYMBIOTEC) Share Price hits fresh 52-week high at Rs 1,195

SYMBIOTEC Share Price is trading at Rs 1,186.90, up 3.72% from the previous close, after touching a fresh 52-week high of Rs 1,195. The company’s market capitalisation stands at Rs 6,790.26 crore, placing the move firmly in focus for SYMBIOTEC Share Price Today and SYMBIOTEC Stock News readers. Univest data confirms the move itself, though no company-specific trigger has been identified. In that context, SYMBIOTEC Share Price matters not because of a claimed trigger, but because the market has already printed a new yearly high and the stock is now being assessed through valuation, sector and peer comparisons.

For SYMBIOTEC Share Price, the latest move also gives a clean snapshot of price action: the stock opened at Rs 1,159, moved between Rs 1,138.65 and Rs 1,195, and is last traded below the day’s high. This makes SYMBIOTEC Share Price Today relevant for readers tracking one-year high names in Healthcare and for those following SYMBIOTEC Stock News, SYMBIOTEC Share News and SYMBIOTEC Market Cap alongside fundamentals.

SYMBIOTEC Share Price Today: Price Action Analysis

Metric	Value
Current Price	Rs 1,186.9
Previous Close	Rs 1,144.35
Today's Move	+Rs 42.55 (+3.72%)
Open	Rs 1,159
High	Rs 1,195
Low	Rs 1,138.65
Market Capitalisation	Rs 6,790.26 crore

SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) traded at Rs 1,186.9 versus the previous close of Rs 1,144.35, a rise of 3.72%. The stock opened at Rs 1,159, reached a high of Rs 1,195 and touched a low of Rs 1,138.65.

SYMBIOTEC Share Price Today reflects a straightforward intraday setup built on verified numbers rather than a stated trigger. The stock is trading at Rs 1,186.90 versus the previous close of Rs 1,144.35, a rise of Rs 42.55 or 3.72%. It opened at Rs 1,159, touched a low of Rs 1,138.65 and reached Rs 1,195, which is also the fresh 52-week high. That means SYMBIOTEC Share Price has already printed its yearly high in the current move and is now trading slightly below that level.

For readers following SYMBIOTEC Share Price Live or SYMBIOTEC Share Price Update, the important point is that the day’s range is fully defined by the numbers already visible: Rs 1,138.65 at the low and Rs 1,195 at the high. Univest data confirms the event, but no company-specific catalyst is established. That makes the current SYMBIOTEC Share Price story one of price action first, explanation second, with no unsupported narrative layered on top.

The event also places SYMBIOTEC Share Price in the 52 Week High Stocks conversation without turning it into an all-time-high claim. Only the one-year high language is justified here. For market readers, SYMBIOTEC Stock Performance now becomes a question of whether the current trade around Rs 1,186.90 can be read alongside the next sections on valuation, growth and sector benchmark data.

SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) Fundamental Analysis

Metric	Value
Market Capitalisation	Rs 6,790.26 crore
P/E Ratio	66.91x
P/B Ratio	4.9x
ROE	11.22%
ROCE	12.41%
EPS	Rs 17.1
Book Value Per Share	Rs 233.38
Dividend Yield	0%

SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) fundamental metrics show P/E 66.91x, P/B 4.9x, ROE 11.22%, ROCE 12.41%. Read together, these ratios describe the company's position rather than a recommendation.

SYMBIOTEC PHARMALAB LTD has a market capitalisation of Rs 6,790.26 crore, which gives readers a sense of company size before judging valuation. On valuation, P/E at 66.91x, P/B at 4.9x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 11.22% and ROCE of 12.41%, helping investors compare shareholder returns and capital efficiency. According to latest Univest data, additional metrics include EPS of Rs 17.1, book value per share of Rs 233.38, dividend yield of 0%, adding context to earnings, balance-sheet value and historical payout. Against the latest Univest same industry benchmark, these figures can be compared with benchmark median P/E of 32.41x, median ROE of 11.74%, median ROCE of 13.63%. These numbers explain the fundamental backdrop without converting the article into a buy or sell view.

Sector and Industry Context

Metric	Value
Sector	Healthcare
Industry	Pharmaceuticals & Drugs
Benchmark Scope	same industry
Company P/E Ratio	66.91x
Benchmark Median P/E	32.41x
Benchmark Average P/E	49.36x
Benchmark P/E Range	3.4x to 699.02x
Company P/B Ratio	4.9x
Benchmark Median P/B	2.89x
Company ROE	11.22%
Benchmark Median ROE	11.74%
Company ROCE	12.41%
Benchmark Median ROCE	13.63%
Company Market Capitalisation	Rs 6,790.26 crore
Benchmark Median Market Cap	Rs 773.14 crore

SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) operates in the Healthcare sector, within the Pharmaceuticals & Drugs industry.

SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) has a P/E ratio of 66.91x, which is above the benchmark median of 32.41x, a difference of +106.45%. The P/E comparison frames valuation; it is not a signal to buy or sell.

SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) has a ROE of 11.22%, which is below the benchmark median of 11.74%, a difference of -4.43%. SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) has a ROCE of 12.41%, which is below the benchmark median of 13.63%, a difference of -8.95%.

Track stocks reaching yearly peaks through the Univest 52-week-high screener. The peer table below provides the company-level comparison.

Peer Comparison

Company	Symbol	Market Cap (Cr)	P/E	P/B	ROE (%)	ROCE (%)
Morepen Laboratories Ltd.	MOREPENLAB	6,608.32	46.32	5	7.96	10.19
Sanofi India Ltd.	SANOFI	7,146.75	21.84	8.56	44.5	55.46
Innova Captab Ltd.	INNOVACAP	7,275.01	46.59	6.42	13.75	15.04
SENORES PHARMACEUTICALS L	SENORES	6,226.21	51.12	6.7	14.14	15.66
Orchid Pharma Ltd.	ORCHPHARMA	6,129.55	699.02	3.87	0.7	1.11

SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) has a P/E ratio of 66.91x compared with the displayed peer median of 46.59x. Peer multiples give relative context only, not a buy or sell view. Its ROE of 11.22% compares with a peer median of 13.75% across the companies shown in the table. ROCE stood at 12.41% versus the displayed peer median of 15.04%, providing a capital-efficiency comparison. SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) has a market capitalisation of Rs 6,790.26 crore. Among the 5 peers shown, 2 have a larger market capitalisation.

Why Investors Are Watching SYMBIOTEC

• SYMBIOTEC Share Price touched a fresh 52-week high of Rs 1,195 and is now trading at Rs 1,186.90.
• The stock is up Rs 42.55, or 3.72%, versus the previous close of Rs 1,144.35.
• SYMBIOTEC Market Cap stands at Rs 6,790.26 crore.
• The P/E ratio is 66.91, while the sector median P/E is 32.41.
• ROE is 11.22% and ROCE is 12.41% against sector medians of 11.74% and 13.63%.

About SYMBIOTEC PHARMALAB LTD

SYMBIOTEC PHARMALAB LTD operates in the Healthcare sector and the Pharmaceuticals & Drugs industry. The company is part of the same industry set used in the sector snapshot and peer comparison, which places SYMBIOTEC Share Price within a broader listed pharmaceutical universe. For readers checking SYMBIOTEC Company News or SYMBIOTEC Latest News, this is the relevant classification context behind the numbers.

The visible company profile here is intentionally factual and limited to the classification and market data available. That keeps SYMBIOTEC Share Price, SYMBIOTEC Stock News and SYMBIOTEC Fundamental Analysis anchored to verified attributes rather than speculative business claims. Univest presents the company through market ratios, sector context and price action, which is enough for a disciplined first read.

Frequently Asked Questions

What is SYMBIOTEC Share Price today?

Ans. SYMBIOTEC Share Price is trading at Rs 1,186.90, up 3.72% from the previous close of Rs 1,144.35. The stock also touched a fresh 52-week high of Rs 1,195 during the move.

Did SYMBIOTEC Share Price hit a fresh 52-week high?

Ans. Yes. SYMBIOTEC Share Price touched a fresh 52-week high of Rs 1,195. The current trade is slightly below that level at Rs 1,186.90, making the one-year high the key reference point.

Why is SYMBIOTEC Share Price in focus today?

Ans. SYMBIOTEC Share Price is in focus because it reached a fresh 52-week high, rose 3.72%, and carries a market capitalisation of Rs 6,790.26 crore. According to Univest data, no company-specific catalyst is established.

What is the market cap of SYMBIOTEC?

Ans. SYMBIOTEC’s market capitalisation is Rs 6,790.26 crore. That places SYMBIOTEC Share Price above the industry median market cap of Rs 773.14 crore and below the industry average of Rs 14,293.1 crore.

How does SYMBIOTEC Share Price compare with the sector P/E?

Ans. SYMBIOTEC Share Price reflects a P/E ratio of 66.91, which is above the industry median of 32.41 and above the industry average of 49.36. This is important in SYMBIOTEC Fundamental Analysis.

What do ROE and ROCE show for SYMBIOTEC?

Ans. SYMBIOTEC reports ROE of 11.22% and ROCE of 12.41%. ROE is near the industry median of 11.74%, while ROCE is below the industry median of 13.63% and the average of 13.4%.

What is SYMBIOTEC’s EPS and book value?

Ans. SYMBIOTEC’s EPS is 17.1 and book value is Rs 233.38. EPS shows earnings attributable to each share, while book value shows the accounting net worth behind each share in SYMBIOTEC Share Price analysis.

Should investors track SYMBIOTEC Share Price on Univest?

Ans. Yes. Univest brings together SYMBIOTEC Share Price, the 52-week high, valuation ratios, market cap and peer context. That makes it easier to follow SYMBIOTEC Share Price Today and broader SYMBIOTEC Stock News in one view.

Track SYMBIOTEC Share Price on Univest

Use SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) live share-price page, Univest 52-week-high screener, Univest market blogs to review live stock data, yearly-high lists and related market analysis.

Readers can track SYMBIOTEC Share Price on Univest for live price movement, market capitalisation, PE Ratio, PB Ratio, ROE, ROCE, EPS, book value and 52-week levels. Univest also keeps the Healthcare sector context and peer comparison together so SYMBIOTEC Share Price Today can be reviewed with the right valuation backdrop.

If you are following SYMBIOTEC Stock News or SYMBIOTEC Share Price News, Univest makes it easier to move from the intraday move to the fundamentals and the sector benchmark in one place. That is especially useful when a fresh 52-week high invites closer stock analysis.